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Abstract
Background: Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate
serum concentrations in obese patients. Few outcome studies exist evaluating this population.Objectives:Of this study were to
(1) determine the association of body mass index (BMI) with clinical outcomes of candidemia patients on standard doses of
anidulafungin and (2) characterize fungal infections by body weight.Methods: A retrospective cohort was conducted to evaluate
hospitalized patients treated for candidemia with anidulafungin at Food and Drug Administration–labeled dosing for at least 72
hours from January 1, 2014, through January 31, 2018. Candidemia was diagnosed by blood culture or T2 magnetic resonance
(T2MR). Patients were compared according to BMI category. Results: One hundred seventy-three patients were included.
Candida albicans and Candida glabrata were identified in 58 (33%) and 57 (33%) patients, respectively. Mortality was comparable
according to BMI category: 4 (36.4%) underweight, 8 (25.8%) normal weight, 16 (32.0%) overweight, 20 (33.9%) obese, and 7
(31.8%) morbidly obese, P ¼ .976. Variables associated with mortality included: severe sepsis (adjusted odds ratio [OR] ¼ 5.1,
95% CI: 1.7-14.8) and liver disease (adjusted OR¼ 3.2, 95% CI: 1.1-9.4). Variables that were protective of mortality included: line
removal (adjusted OR¼ 0.05, 95% CI: 0.02-0.2) and receipt of anidulafungin for at least 5 days (adjusted OR¼ 0.35, 95% CI: 0.15-
0.8). Conclusion: There was no difference detected in mortality among patients with candidemia across BMI category. Larger
studies are needed to confirm whether standard doses of anidulafungin are sufficient for candidemia in obese patients.
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Introduction
Obese patients may have altered pharmacokinetic parameters
when compared with normal weight patients due to their body
habitus and altered drug clearance. Differences in volume of
distribution and systemic clearance may indicate that these
patients require a larger dose of some antimicrobials to
achieve the same minimum inhibitory concentrations (MIC)
as normal weight patients.1,2 Comparative clinical outcomes
data for dosing antifungal agents in obesity are scarce, and
published experience with the echinocandin class is limited to
case reports.3
Recently, Bader and colleagues questioned current dosing
strategies for echinocandins, including anidulafungin. Monte
Carlo simulations demonstrate that anidulafungin is unlikely
to achieve target attainment with Food and Drug Administra-
tion (FDA)–labeled dosing.4 In hospitalized patients under-
going laparoscopic gastric bypass or sleeve surgery on
anidulafungin for surgical prophylaxis, anidulafungin concen-
trations are approximately 33% lower than expected for a
normal weight adult.5 In this patient population, anidulafungin
dosing may need to be increased from FDA-labeled doses to
achieve target concentrations and maintain efficacy. A 50%
increase from anidulafungin FDA-labeled loading and mainte-
nance dose has been proposed for patients who are morbidly
obese.5,6 However, current literature is lacking to determine
whether obese patients treated with standard anidulafungin
doses have poorer clinical and microbiologic outcomes than
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normal weight patients. The purpose of the present study was to
characterize bloodstream infection with Candida species and
compare patient outcomes with anidulafungin treatment, stra-
tified by body mass index category (BMI).
Methods
Study Design, Setting, and Patient Population
A retrospective cohort was conducted over a 4-year time period
from January 1, 2014, through January 31, 2018, at a 4-hospital
health system, Henry Ford Health system, in metropolitan
Detroit, Michigan. All 4 hospitals utilize a centralized clinical
microbiology laboratory and have antimicrobial stewardship
programs. Anidulafungin was recommended in the antimicro-
bial stewardship guideline as first-line therapy for candidemia
among intensive care unit patients and patients with a history of
azole exposure. The institutional guideline recommended a
minimum of 3 to 5 days of anidulafungin prior to azole switch.
Anidulafungin was restricted to infectious diseases approval
throughout the entire study. Restriction was supported by an
electronic medical record order entry panel which bundled
Infectious Diseases consultation, the anidulafungin loading
dose, and maintenance dose. This study was approved by the
institutional review board on June 7, 2018 (#11755).
The study population included all hospitalized adult patients
who received anidulafungin 100 mg intravenously daily for at
least 72 hours and who had a diagnosis of candidemia, defined
as at least one positive blood culture or T2 magnetic resonance
(T2MR) for Candida species (T2 Biosystems). Patients were
not excluded if they did not receive the 200 mg loading dose.
Patients receiving any immunosuppression agents posttrans-
plant or who had neutropenia, defined as absolute neutrophil
count <500 cells/mm3 or <1000 cells/mm3 but expected to
decrease to <500 cells/mm3 within the next 24 to 48 hours at
time of positive blood culture or T2MR, were excluded.
Patients were also excluded if the indication for antifungal
therapy was endocarditis, osteomyelitis, or meningitis, and if
the initial diagnosis of candidemia was made at an outside
facility.
Outcomes and Definitions
Patients included in the study were categorized into BMI
groups as defined by the World Health Organization and
National Institutes of Health: underweight (BMI < 18.5), nor-
mal weight (BMI 18.5-24.9), overweight (BMI 25-29.5), obese
(BMI 30-39), and extremely obese (BMI  40). Body mass
index was calculated by the study investigators by taking the
patient’s weight in kilograms and dividing it by the patient’s
height in meters squared using the measurements in the elec-
tronic medical record that were taken nearest to the first dose of
anidulafungin.
The primary outcome was 30-day all-cause mortality.
Thirty-day all-cause mortality was determined by medical
record review by the primary investigator. Patients were pre-
sumed to have survived if they were discharged alive prior to
30 days of follow-up and there was no documentation in the
electronic medical record indicating that they were deceased.
Secondary outcomes included: 14-day global clinical cure
rates, suspected Candida eye involvement, and recurrence with
need for antifungal reinitiation. Global clinical cure was
defined as achieving both microbiological success and clinical
cure. Microbiological success was defined as documented, 2
subsequent negative blood cultures 24 hours apart, or pre-
sumed, one repeat negative culture with no recurrence. For
patients diagnosed by T2MR, microbiological success was pre-
sumed if the patient had no positive blood cultures and a suc-
cessful clinical response to antifungal therapy. If a patient did
not achieve documented or presumed microbiological success
as defined by the above definitions, he or she was classified as
microbiological failure. Clinical cure was defined as the reso-
lution of signs and symptoms of invasive candidiasis and no
need for additional systemic antifungal therapy. Candida eye
involvement was diagnosed by ophthalmology consult notes
present in the electronic medical record. Recurrent fungal
infection was defined as a mycologically confirmed infection
with the same baseline Candida species within 6 weeks after
primary fungal culture or a suspected infection that required
additional systemic antifungal therapy after the end of all anti-
fungal therapy in patients previously considered to have a suc-
cessful response. Optimal fluconazole dose was defined as
fluconazole 6 mg/kg of actual body weight or 3 mg/kg if the
patient’s creatinine clearance was less than 30 mL/min or the
patient was on hemodialysis while receiving fluconazole. In
patients with fluconazole MIC 16 to 32 mg/mL, 12 mg/kg was
considered optimal. Optimal voriconazole dosing was defined
as voriconazole 4 mg/kg, as defined by the Infectious Diseases
Society of America Candidiasis Guidelines.7
Data Collection and Analysis
Patients were identified by positive blood culture and T2MR
results in the study time frame using Theradoc® (Premier, Inc)
and Epic version 2017 (Epic Systems Corp) and enrolled con-
secutively. Data were extracted from electronic medical
records using a standardized case report form. Past medical
history and age were collected at the time of admission.
Sequential organ failure assessment score was collected at the
time of candidemia identification. Candidemia risk factors,8
microbiology data, source control, antifungal therapy, and
ophthalmology data were collected from the time of first pos-
itive blood culture or T2MR through hospital discharge. Micro-
biology data included number and timing of positive blood
cultures or T2MR, Candida species, antifungal susceptibilities,
and time to blood culture clearance. Global clinical cure,
microbiological cure, and clinical cure were evaluated at 14
days from the time of first positive blood culture or T2MR.
Recurrence of candidemia and need for additional antifungal
therapy were evaluated until 6 weeks after the first positive
blood culture or T2MR, if data were available. Finally, Can-
dida spp. MICs were determined by the microbiology
2 Journal of Pharmacy Practice XX(X)
laboratory using microdilution multiwell plates and was per-
formed upon request only.
Statistical analyses were performed as follows: Dichoto-
mous data were analyzed by Pearson w2 or Fisher exact test,
as appropriate, ordinal data by Kruskal-Wallis test, and contin-
uous data by Student t test or Mann-Whitney U test, as appro-
priate. Logistic regression analysis was performed to evaluate
variables independently associated with mortality while con-
trolling for confounding factors. Variables with a P value of <.2
in bivariate analysis and with clinical rationale for a potential
association with mortality were considered for inclusion. In the
final model, an adjusted odds ratio with a CI that did not
include 1.0 was considered statistically significant. All statis-
tical analyses were performed using SPSS software version
22.0 (IBM Inc). The sample of size of 340 patients was deter-
mined assuming alpha ¼ .05, beta ¼ .20, and an anticipated
effect size of 15% for mortality in candidemia. A baseline
mortality rate of 35% was assumed for normal weight
patients.9,10
Results
Four hundred sixty-three patients with candidemia were
screened for inclusion; 290 patients were excluded: 226
received an echinocandin for less than 72 hours, 26 patients
had endocarditis, 25 patients were receiving immunosuppres-
sion for a transplanted organ, and 13 patients were neutropenic,
pediatric, had osteomyelitis, or were diagnosed at an outside
hospital; 173 patients met eligibility criteria and were included
in the study population; 171 were managed by an Infectious
Diseases consultant. Patient characteristics and candidemia risk
factors are displayed in Table 1. Most patients had a central line
in place at the time of positive culture/T2MR and over half of
the patients had sepsis with end organ dysfunction.
Candida albicans (33%) and Candida glabrata (33%) were
the most common species identified (Table 2). Sources of
infection were no different between BMI groups, with the most
common source of infection identified as the central line
(43.3%), followed by an unknown source (30%) and intra-
abdominal infection (18%). Species identified by blood culture
were no different when compared with T2MR. Most patients
did not have antifungal susceptibilities performed; however, 46
fluconazole, 14 voriconazole, and 34 anidulafungin MICs were
available to evaluate. The MIC50 and MIC90 are described in
Table 3. Anidulafungin MICs were low for almost all patients
but were greater than or equal to 1 mg/mL in 5 Candida para-
psilosis species. This elevation in anidulafungin MIC was not
seen in any other species.
Median days to administration of anidulafungin was one day
from positive T2MR or positive culture for yeast. All but one
patient received a 200-mg loading dose of anidulafungin.
Patients who survived that had therapy de-escalated to a tria-
zole were less likely to receive an optimal dose, 46 (59%) of 78,
compared to patients who expired, 18 (82%) of 22. All doses
considered suboptimal were lower than recommended. Patients
who survived received more days of anidulafungin and more
days of total antifungal therapy compared to patients who
expired: 5 (3-14) days versus 4 (3-6) days and 18 (15-29) days
versus 8 (5-11), respectively. Similarly, survivors were more
likely to achieve source control compared to patients who
Table 1. Patient Characteristics.
N (%) BMI <18.5, N ¼ 11 BMI 18.5-24, N ¼ 31 BMI 25-29, N ¼ 50 BMI 30-39, N ¼ 59 BMI 40, N ¼ 22
Female 3 (27.3) 14 (45.2) 21 (42.0) 26 (44.1) 16 (72.7)a
Pulmonary conditionb 3 (27.3) 6 (19.4) 11 (22.0) 16 (27.1) 11 (50.0)a
Congestive heart failure 2 (18.2) 3 (9.7) 10 (20.0) 12 (20.3) 5 (22.7)
Diabetes mellitus 3 (27.3) 8 (25.8) 16 (32.0) 26 (44.1) 12 (54.5)
Cancer 4 (36.4) 12 (38.7)a 12 (24.0) 13 (22.0) 2 (9.1)
Liver disease 1 (9.1) 4 (12.9) 10 (20.0) 4 (6.8) 4 (18.2)
Chronic kidney disease 2 (18.2) 6 (19.4) 14 (28.0) 15 (25.4) 1 (4.5)
SOFA scorea 4 (1.5-7) 5 (2-8) 6 (3.25-10) 9 (4-12) 8.5 (5-11.75)
Anidulafungin for 5 daysc 5 (45.5) 16 (51.6) 29 (58.0) 29 (49.2) 11 (50.0)
Candidemia risk factors
Total parenteral nutrition 3 (27.3) 6 (19.4) 6 (12.0) 4 (6.8) 1 (4.5)
Surgeryd 1 (9.1)a 15 (48.4) 25 (50.0) 32 (54.2) 12 (54.5)
Multifocal colonizatione 0 (0) 1 (3.2) 5 (10.0) 8 (13.6) 2 (9.1)
Severe sepsisf 6 (54.5) 18 (58.1) 33 (67.3) 44 (74.6) 18 (81.8)
Central line 11 (100) 26 (83.9) 44 (88.0) 53 (89.9) 21 (95.5)
Median Candida score8 3 3 3 3 3
Abbreviations: BMI, body mass index; SOFA, sequential organ failure assessment; T2MR, T2 magnetic resonance.
aP < .05.
bThe patient had a chronic pulmonary disease listed in their past medical history, including cystic fibrosis, chronic obstructive pulmonary disease, asthma,
pulmonary fibrosis, and interstitial lung disease.
cThe patient received anidulafungin for at least 5 days prior to stepping down to triazole therapy.
dAny recent surgery in the prior 30 days to positive blood culture of T2MR.
eCandida isolated from 2 noncontiguous sites: oropharynx, stomach, urine, or tracheal aspirate.
fThe patient has 2 systemic inflammatory response syndrome criteria plus signs of end organ damage.
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expired, 111 (94%) of 118 and 38 (69%) of 55, respectively,
and have the central line removed, 95 (94%) of 101 and 28
(52%) of 53, respectively. Time to central line removal did not
differ between patients who survived and those who expired, 3
days (1.75-4.5) versus 2 days (1-4.75).
The primary end point of mortality was not significantly
different between the BMI groups: underweight: 4 (36.4%),
normal: 8 (25.8%), overweight: 16 (32.0%), obese: 20
(33.9%), and morbidly obese: 7 (31.8%), P ¼ .976. In logistic
regression, sepsis with end organ damage and liver disease
were independent predictors of mortality, while receipt of an
echinocandin for at least 5 days and central-line removal were
protective (Table 4). Global clinical cure was achieved in 103
(87%) of patients who survived. Microbiological success was
achieved in 116 (98.3%) of patients who survived: 88 (74.6%)
documented and 28 (23.7%) presumed. In patients who died, 3
(5.5%) achieved global clinical cure and 51 (92.8%) achieved
microbiological clearance (47.3% documented and 45.5% pre-
sumed). Among survivors, 5 patients had relapse of candide-
mia, and 16 patients received additional antifungal therapy. Of
patients who had evaluation for Candida eye involvement,
more patients who expired had involvement at 10 (26.3%)
compared to 16 (16.8%) who survived. Distribution of Candida
eye involvement by BMI was similar for those who underwent
evaluation: underweight: 1 (12.5%) of 8, normal: 6 of 24
(25.0%), overweight: 7 of 39 (17.9%), obese: 9 of 42
(21.4%), and morbidly obese: 3 of 20 (15.0%), P ¼ .971.
Discussion
This study provides valuable patient outcome information on
the relationship between BMI, echinocandin dose, and out-
come. In the absence of therapeutic drug monitoring, an out-
come assessment by BMI category is an important surrogate.
The current echinocandin pharmacodynamic target of area
under the curve to MIC ratio was derived in neutropenic murine
models.11 Although serum concentrations appear to be lower in
obese patients, previous studies have reported successful out-
comes with FDA-labeled echinocandin doses for candidiasis.
Zomp and colleagues published a case report of a patient who
weighed 230 kg with a corresponding BMI of 102 kg/m2 that
was treated with the FDA-labeled dose of micafungin for a C
glabrata urinary tract infection that was suspected to have dis-
seminated. Although micafungin serum concentrations were
half of what is expected in normal weight adults, the patient
had a successful clinical outcome with sterilization of cul-
tures.12 Furthermore, in a post hoc evaluation of 9 prospective
clinical trials of caspofungin that evaluated safety and efficacy,
clinical outcomes were compared in normal weight versus
overweight patients. Body mass index category was not asso-
ciated with clinical success or failure in this study, with clinical
success ranging between 71% and 77% between the cate-
gories.13 The “obesity paradox” may also play role in outcomes
for these infections. Although obesity is associated with heigh-
tened morbidity and mortality for most adults, there are some
conditions and infections that it has been described as protec-
tive for. An example of one of these conditions is severe sepsis,
and no data exist that pertain to candidemia specifically.14
Anidulafungin MICs in this study were within expected
values for the Candida species that were evaluated. The anti-
fungal stewardship program and the quality of management of
candidemias may have contributed to the overall success of
patients in all BMI groups. Most patients had anidulafungin
administered within 24 hours of candidemia onset, received the
appropriate FDA-labeled anidulafungin loading dose, had
Table 3. Antifungal MIC Distribution.
Antifungal MIC50 (mg/mL) [IQR] MIC90 (mg/mL)
Fluconazole, N ¼ 46 4.0 [1.0-8.0] 16.0
Voriconazole, N ¼ 14 0.25 [0.12-0.5] 2.0
Anidulafungin, N ¼ 34 0.03 [0.03-0.12] 1.0
Abbreviations: IQR, interquartile range; MIC, minimum inhibitory
concentration.
Table 2. Candida spp. Characteristics by BMI.
N (%) BMI <18.5, N ¼ 11 BMI 18.5-24, N ¼ 31 BMI 25-29, N ¼ 50 BMI 30-39, N ¼ 59 BMI 40, N ¼ 22
Candida albicans 3 (27.3) 6 (19.4) 10 (20.0) 17 (28.8) 4 (18.2)
Candida glabrata 2 (18.2) 7 (22.6) 11 (22.0) 16 (27.1) 4 (18.2)
Candida parapsilosis 0 4 (12.9) 2 (4.0) 6 (10.2) 3 (13.6)
Other Candida spp. 2 (18.2) 6 (19.4) 9 (18.0) 10 (16.9) 4 (18.2)
T2 Candida albicans/tropicalis 4 (36.4) 6 (19.4) 7 (14.0) 8 (13.6) 2 (9.1)
T2 Candida glabrata/krusei 0 2 (6.5) 12 (24.0) 8 (13.6) 1 (4.5)
T2 Candida parapsilosis 2 (18.2) 2 (6.5) 4 (8.0) 3 (5.1) 5 (22.7)
Anidulafungin MIC 0.12 mg/mL 0 3 (9.7) 2 (4.0) 6 (10.2) 0
Source
Intra-abdominal 1 (9.1) 4 (12.9) 13 (26.0) 8 (13.6) 5 (22.7)
Central line 7 (63.6) 15 (48.4) 21 (42.0) 23 (39.0) 9 (40.9)
Genitourinary 0 3 (9.7) 3 (6.0) 3 (5.1) 1 (4.5)
Skin 0 0 1 (2.0) 0 2 (9.1)
Other 0 0 0 2 (3.4) 0
Unknown 3 (27.3) 9 (29.0) 12 (24.0) 23 (39.0) 5 (22.7)
Abbreviations: BMI, body mass index; MIC, minimum inhibitory concentration.
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source control achieved, and were transitioned to an appropri-
ate weight-based fluconazole dose.
Interestingly, Candida epidemiology did not differ between
the BMI groups. Some information suggests that obesity
changes the mycobiome, and that differences in infecting Can-
dida species would be expected.15 Source of Candida infection
did not differ between BMI groups.
There are some limitations to this study. Some of this
study’s findings could have been affected by survivor bias,
including days of antifungal therapy, achievement of source
control, and ophthalmologic examination completion. Study
data were dependent on electronic medical record documenta-
tion, which may have led to misclassification bias in some
patient information, such as determining the source of infec-
tion. Fifty-two (30%) of patients in our cohort did not have a
source identified for candidemia based upon chart documenta-
tion. Source control of candidemia is a known predictor of
survival, and this may have affected our outcomes. It is possi-
ble that our results could be explained from a confounding
variable not evaluated in the study. Since this study was com-
pleted over a 4-year time span, improvements in the manage-
ment of candidemia are possible. However, there was no
evidence of maturation according to the trend in mortality by
year: 2014 (36%), 2015 (20%), 2016 (45%), and 2017 (28%).
Unfortunately, there were incomplete antifungal susceptibility
data in this study, and the majority of isolates did not have
testing performed. Interestingly, 5 of the 6 C parapsilosis spe-
cies that had anidulafungin MIC testing completed had MICs
1 mg/mL. All of these patients survived, and all were transi-
tioned to fluconazole definitive therapy. However, 23 C para-
psilosis infections did not have anidulafungin MIC testing
performed, so conclusions cannot be drawn for this subgroup.
Finally, we did not meet our intended sample size. Many eli-
gible patients did not receive an echinocandin for at least 72
hours, which excluded them from the study. It was impractical
to extend our study because data older than 2014 was not
available in the current electronic health record.
Conclusion
In conclusion, we did not detect a difference in 30-day all-
cause mortality when comparing candidemia patients treated
with FDA-label dosing of anidulafungin by BMI category,
although our study of 173 candidemia patients was underpow-
ered. Additionally, we did not identify differences in Candida
spp. or resistance across BMI categories. Larger studies with
therapeutic drug monitoring are needed to determine whether
routine, off-label dose adjustments are necessary in obesity or
morbid obesity.
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